CD11b is a surface protein found on most innate immune cells, and it serves as a master regulator of how those cells stick to blood vessel walls, crawl toward sites of infection, and engulf invaders. Formally known as integrin alpha M (αM), CD11b pairs with a partner subunit called CD18 to form the receptor Mac-1, also designated complement receptor 3 (CR3). This receptor sits at a crossroads of immunity: it helps the body fight bacteria and clear debris, but when it malfunctions or is hijacked, it contributes to autoimmune disease, sepsis-related organ damage, and even cancer progression. Understanding what CD11b does, how genetic variants alter its behavior, and how researchers are now trying to manipulate it pharmacologically opens a window into some of the most active areas of immunology and translational medicine.
How CD11b Works at the Molecular Level
CD11b does not work alone. It forms a two-part complex with CD18, and this pairing is essential for function. The resulting heterodimer, Mac-1, belongs to the β2 integrin family, a group of adhesion molecules critical for leukocyte adhesion, migration, and broader immune functions.1PubMed Central. Small molecule-mediated activation of the integrin CD11b/CD18 reduces inflammatory disease Think of integrins as molecular velcro on the surface of immune cells. When the body detects an infection or tissue damage, Mac-1 switches from a resting, low-adhesion shape to an active, high-adhesion shape. That conformational change is what allows immune cells to grab onto the lining of blood vessels and then squeeze through into tissues.
A key trigger for this shape change involves phosphorylation of a specific amino acid on the CD11b chain’s intracellular tail. When serine 1126 gets phosphorylated in neutrophils, Mac-1 gains the ability to bind cellular ligands called ICAM-1 and ICAM-2, which are displayed on endothelial cells. Mutating that phosphorylation site blocks ICAM binding, but interestingly it does not prevent Mac-1 from recognizing other ligands like the complement fragment iC3b or denatured proteins.2Blood. α-Chain phosphorylation of the human leukocyte CD11b/CD18 (Mac-1) integrin is pivotal for integrin activation to bind ICAMs and leukocyte extravasation This means the integrin is not an all-or-nothing switch: different activation signals unlock different binding capabilities, letting the cell fine-tune its response depending on context.
Adhesion, Crawling, and Getting Through Blood Vessel Walls
One of Mac-1’s headline jobs is helping neutrophils leave the bloodstream and reach inflamed tissue. The process involves multiple steps: the neutrophil first rolls along the vessel wall, then arrests (sticks firmly), polarizes into a teardrop shape, crawls along the endothelium, and finally passes through the vessel wall into tissue. Studies using mice lacking either CD11b or the related integrin CD11a (LFA-1) have mapped which integrin handles which step. LFA-1 is the primary driver of shear-resistant arrest, the moment the neutrophil slams to a halt. Mac-1, by contrast, dominates the polarization step, where the cell orients itself for directional movement. Both integrins contribute to crawling, and both rely on endothelial ICAM-1 and ICAM-2 as their docking partners.3The Journal of Immunology. β2 Integrin–Mediated Crawling on Endothelial ICAM-1 and ICAM-2 Is a Prerequisite for Transcellular Neutrophil Diapedesis across the Inflamed Blood–Brain Barrier
This division of labor has practical significance, especially at the blood-brain barrier. Neutrophil crawling on brain endothelium before crossing into the central nervous system depends on both integrins and both ICAMs. Blocking either integrin partially, or both together, disrupts the process. That makes Mac-1 a relevant target for neuroinflammatory conditions where neutrophil infiltration causes damage.
Phagocytosis and Complement Recognition
Beyond adhesion, Mac-1 doubles as complement receptor 3 (CR3). In this capacity it recognizes iC3b, a fragment of complement protein C3 that gets deposited on the surface of bacteria, dead cells, and other targets flagged for clearance. Binding iC3b triggers actin-dependent phagocytosis, essentially swallowing the target whole. CR3 also recognizes a remarkably wide range of other ligands, including microbial surface molecules, fibrinogen, and denatured albumin.4PubMed Central. Phagocytosis via complement receptor 3 enables microbes to evade killing by neutrophils
CD11b also participates in clearing apoptotic cells, a housekeeping function critical for resolving inflammation. Blocking CD11b on immature dendritic cells with a specific antibody inhibited their ability to phagocytose apoptotic cells, confirming that this integrin is part of the cleanup machinery.5PubMed. The role of CD11b in phagocytosis and dendritic cell development When dead cells are not cleared efficiently, the debris can fuel autoimmune reactions, a point that becomes relevant when discussing lupus.
Which Cells Carry CD11b
CD11b shows up on nearly every cell type in the innate immune system. Neutrophils, monocytes, macrophages, dendritic cells, and natural killer cells all display it. In the brain, microglia are the resident CD11b-expressing cells. The level of expression is not static: it increases as myeloid precursors mature. During monocyte development, for instance, CD11b expression appears at the promonocyte stage and grows brighter as the cells mature further, alongside markers like CD14, CD64, and HLA-DR.6Methods in Cell Biology. Immunophenotypic Pattern of Myeloid Populations by Flow Cytometry Analysis – Section: Monocytes Cytokines also push CD11b up: granulocyte colony-stimulating factor (G-CSF), a growth factor widely used clinically to boost neutrophil production, stimulates synthesis and surface display of both the αM and β2 integrin subunits.7PubMed Central. Control of myeloid-specific integrin alpha Mbeta 2 (CD11b/CD18) expression by cytokines is regulated by Stat3-dependent activation of PU.1
Because CD11b is so broadly expressed on myeloid cells, it has become one of the standard markers used in flow cytometry panels to identify and sort immune cell populations, a point explored further in the diagnostics section below.
Genetic Variants and Lupus
One of the strongest disease links for CD11b involves systemic lupus erythematosus (SLE). The gene encoding CD11b is called ITGAM, and several single-nucleotide polymorphisms in ITGAM have been associated with lupus risk. A meta-analysis pooling data from multiple studies found that the minor allele of the variant rs1143679 carried an overall odds ratio of roughly 1.8 for SLE, meaning carriers had nearly double the risk. Homozygous carriers of the risk allele faced an even steeper odds ratio, around 3.5 compared to non-carriers.8PubMed. Association of ITGAM polymorphism with systemic lupus erythematosus: a meta-analysis Additional ITGAM variants (rs1143683, rs9888739, rs1143678) were also significantly associated with SLE, though with somewhat smaller effect sizes.
The connection is not limited to systemic lupus. A separate study found that ITGAM polymorphisms conferred an even stronger association with discoid lupus, the skin-predominant form, than with SLE overall. For discoid rash specifically, the odds ratio climbed to about 3.8.9PLoS ONE. Polymorphisms of the ITGAM Gene Confer Higher Risk of Discoid Cutaneous Than of Systemic Lupus Erythematosus Why would a dysfunctional CD11b predispose to lupus? The leading hypothesis ties back to apoptotic cell clearance: if Mac-1 variants impair the ability of phagocytes to swallow dead cells efficiently, uncleared debris exposes nuclear antigens to the immune system, triggering autoantibody production. Separate evidence from knockout mice supports this logic, showing that CD11b deficiency amplifies B cell receptor signaling and leads to elevated antigen-specific antibody responses, including the kind of high-affinity IgG that characterizes lupus flares.10PubMed Central. Integrin CD11b negatively regulates B cell receptor signaling to shape humoral response during immunization and autoimmunity
CD11b in Sepsis and Acute Lung Injury
While chronic autoimmune disease represents one extreme of CD11b involvement, acute overwhelming infection sits at the other. During gram-negative sepsis, massive neutrophil activation leads to upregulation of Mac-1, which drives neutrophils into the lungs where they clog the microcirculation. In a mouse transgenic model, inactivating CD11b interfered with neutrophil infiltration into the lungs following E. coli challenge and prevented the increase in microvessel permeability and edema that characterizes early septic lung injury.11PubMed. Inactivation of CD11b in a mouse transgenic model protects against sepsis-induced lung PMN infiltration and vascular injury
Intravital lung imaging in sepsis models has visualized this process in real time. Mac-1-upregulated neutrophils form aggregates that block pulmonary capillaries, creating dead-space regions where gas exchange cannot occur. Administering a Mac-1 inhibitor restored capillary flow and improved oxygenation.12European Respiratory Journal. Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury These findings paint a picture in which CD11b is both a hero and a villain: necessary for pathogen clearance but capable of causing collateral damage when activated too broadly.
Knockout studies add another layer. Mice completely lacking CD11b fare worse when infected with methicillin-resistant Staphylococcus aureus (MRSA), showing significantly higher mortality tied to an exaggerated inflammatory cytokine response. Without CD11b, macrophages overproduce TNF-α and IL-6, and NF-κB signaling runs unchecked.13PubMed Central. CD11b Deficiency Exacerbates Methicillin-Resistant Staphylococcus aureus-Induced Sepsis by Upregulating Inflammatory Responses of Macrophages So the problem in sepsis is not merely too much CD11b activity; it is dysregulated activity. The integrin normally restrains some inflammatory pathways while enabling others, and losing that braking function can be just as dangerous as excessive adhesion.
How Pathogens Exploit CD11b for Immune Evasion
Some of the most dangerous bacteria have evolved to use CD11b’s own phagocytic function against the host. The highly virulent Francisella tularensis, the agent of tularemia, coats itself with complement C3 in the bloodstream. When human macrophages internalize the opsonized bacteria via CR3, the bacterium suppresses the pro-inflammatory cytokine response that would normally follow phagocytosis. Knocking down CD11b expression with siRNA restored the inflammatory response, confirming that the bacterium specifically exploits CR3-mediated uptake to slip into macrophages quietly.14PLOS Pathogens. Fine Tuning Inflammation at the Front Door: Macrophage Complement Receptor 3-mediates Phagocytosis and Immune Suppression for Francisella tularensis A related dynamic has been described for Leishmania parasites, which similarly use CR3 as a gateway into phagocytic host cells.15PubMed Central. Complement receptor 3 deficiency influences lesion progression during Leishmania major infection in BALB/c mice
More broadly, a review of neutrophil phagocytosis found that CR3-mediated uptake can actually enable microbial survival by routing pathogens into intracellular compartments where killing mechanisms are less effective compared to uptake through other receptors.4PubMed Central. Phagocytosis via complement receptor 3 enables microbes to evade killing by neutrophils This is a recurring theme in immunology: the same receptor that protects the host under normal circumstances becomes a liability when a pathogen has evolved to subvert it.
CD11b in Cancer and the Tumor Microenvironment
CD11b has gained significant attention in cancer biology, largely because it marks a population of immune cells called myeloid-derived suppressor cells (MDSCs) that tumors recruit to shut down anti-tumor immunity. MDSCs are immature myeloid cells that accumulate in the blood, bone marrow, and tumor tissue of cancer patients. They suppress T cell activation through multiple mechanisms, including depleting amino acids that T cells need, blocking T cell migration, and promoting the expansion of regulatory T cells. Beyond immunosuppression, MDSCs encourage tumor progression by promoting blood vessel formation via factors like VEGF and by remodeling the surrounding tissue with matrix metalloproteinases.16Archives of Medical Science. Prognostic role of CD11b+ myeloid-derived suppressor cells in oral squamous cell carcinoma
The relationship between MDSCs and cancer stage has been documented across several tumor types. In pancreatic adenocarcinoma, for example, MDSCs are abundant in both bone marrow and the peripheral circulation and correlate with disease progression.17iLIVER. Myeloid-derived suppressor cells in cancer Laboratory work co-culturing human blood cells with diverse tumor cell lines has identified at least two distinct MDSC subsets: one characterized by high CD33 expression and another marked by CD11b positivity with low CD33 and low HLA-DR. The CD11b-bright subset’s induction depended on different tumor-derived signals (particularly FLT3L and TGF-β) compared to the CD33-bright subset, but both expressed enzymes associated with immune suppression, including inducible nitric oxide synthase, NADPH oxidase, and arginase-1.18PubMed Central. Functional characterization of human Cd33+ and Cd11b+ myeloid-derived suppressor cell subsets induced from peripheral blood mononuclear cells co-cultured with a diverse set of human tumor cell lines
CD11b in Transplantation
Organ transplantation presents yet another context where CD11b shapes outcomes. In lung transplantation, a severe complication called primary graft dysfunction (PGD) occurs when donor-derived immune cells left in the transplanted organ trigger an inflammatory cascade after reperfusion. Nonclassical monocytes retained in the donor lung release chemokines that recruit recipient neutrophils, sparking tissue damage. CD11b normally keeps this process in check by suppressing toll-like receptor (TLR) signaling in those monocytes. When researchers transplanted lungs from CD11b-deficient donor mice into normal recipients, they observed significantly increased neutrophil infiltration, worse lung injury scores, and lower oxygen levels compared to transplants from normal donors.19JCI Insight. CD11b suppresses TLR activation of nonclassical monocytes to reduce primary graft dysfunction after lung transplantation The implication is that CD11b on donor monocytes acts as a natural brake on post-transplant inflammation, and understanding how to preserve or enhance that brake could improve graft survival.
CD11b in Atherosclerosis
Monocytes and macrophages are central players in atherosclerotic plaque formation, and CD11b is their defining surface integrin. In experiments using transgenic mice carrying a diphtheria toxin receptor driven by the CD11b promoter, researchers selectively depleted monocytes and macrophages and watched what happened to plaque development. Depleting these cells markedly reduced new plaque formation and altered plaque composition, lowering collagen content and shrinking the necrotic core. Intriguingly, established plaques proved more resistant to monocyte depletion, suggesting that macrophages already embedded in mature plaques are self-sustaining or harder to eliminate.20PubMed Central. Monocyte/macrophage suppression in CD11b diphtheria toxin receptor transgenic mice differentially affects atherogenesis and established plaques This finding underscores why prevention strategies targeting early inflammation differ from treatments aimed at stabilizing existing plaques.
Diagnostic Applications in Flow Cytometry
Because CD11b appears reliably on myeloid cells and its expression level shifts with cell maturity and activation state, it has become a standard marker in clinical and research flow cytometry panels. A flow cytometric method for evaluating CD11b upregulation on peripheral blood neutrophils and monocytes in vivo was described decades ago, and it remains part of standard practice.21Journal of Immunological Methods. Flow cytometric determination of CD11b upregulation in vivo
In clinical hematology labs, CD11b expression helps identify cell lineage and maturation stage. Its brightness distinguishes immature from mature monocytes and helps separate monocytic from granulocytic differentiation paths.6Methods in Cell Biology. Immunophenotypic Pattern of Myeloid Populations by Flow Cytometry Analysis – Section: Monocytes In cancer research, CD11b staining is used alongside other markers to quantify MDSC populations in patient blood and tumor tissue, providing prognostic information and a readout for immunotherapy trials. When a treatment aims to reprogram the myeloid compartment of a tumor, tracking CD11b-positive populations before and after therapy is one way to measure whether the drug is reaching its target.
Therapeutic Targeting of CD11b
The dual nature of CD11b, anti-inflammatory brake and pro-inflammatory adhesion molecule, has created two distinct therapeutic strategies, and the counterintuitive approach is currently generating the most excitement.
The intuitive strategy is blocking Mac-1 to prevent excessive neutrophil infiltration. This works in animal models of sepsis-induced lung injury, where Mac-1 inhibitors restore pulmonary microcirculation.12European Respiratory Journal. Neutrophils disturb pulmonary microcirculation in sepsis-induced acute lung injury But the knockout data show that eliminating CD11b entirely backfires: mice without CD11b develop runaway NF-κB-driven inflammation and die more readily from bacterial infections.13PubMed Central. CD11b Deficiency Exacerbates Methicillin-Resistant Staphylococcus aureus-Induced Sepsis by Upregulating Inflammatory Responses of Macrophages That paradox has pushed researchers toward the second strategy: activating CD11b rather than blocking it.
Small molecules called leukadherins bind to CD11b/CD18 and allosterically lock it in its active conformation. Rather than freeing leukocytes to migrate wildly, this enhanced adhesion actually pins them in place, reducing their migration into tissues and decreasing inflammatory injury in vivo. The concept is that a cell stuck firmly to the vessel wall cannot squeeze into the tissue and cause damage. Early data found that leukadherins outperformed activating antibodies in reducing vascular injury.22Circulation. Small Molecule Agonists of Integrin Cd11b/cd18 Are Significantly Better than Activating Antibodies in Reducing Vascular Injury
The cancer field has built on this activation strategy. CD11b agonists reprogram tumor-associated macrophages by simultaneously repressing NF-κB signaling (through degradation of the p65 protein) and activating interferon gene expression through the STING/STAT1 pathway. The interferon activation depends on the tumor microenvironment and is amplified by cytotoxic therapies like chemotherapy. One such agonist, GB1275, has reached phase I clinical studies in humans, where tissue analysis confirmed that it activates STING and STAT1 signaling in macrophages within human tumors.23PubMed Central. Context-dependent activation of STING-interferon signaling by CD11b agonists enhances anti-tumor immunity The idea is that pushing tumor macrophages from an immunosuppressive state into an inflammatory, interferon-producing state could make tumors more visible to the adaptive immune system, especially when combined with checkpoint inhibitors or chemotherapy.
Microglia, Synaptic Pruning, and Neurodegeneration
In the brain, microglia are the primary CD11b-expressing cells, and their roles go well beyond classical immune defense. Microglia sculpt neural circuits during development by pruning excess synapses, a process that requires complement-mediated tagging of unwanted connections followed by phagocytic removal. This same machinery appears to reactivate inappropriately in neurodegenerative conditions. In Alzheimer’s disease, disruptions in microglia-synapse interactions may contribute to the synapse loss and cognitive impairment that define the disorder.24PubMed Central. New insights on the role of microglia in synaptic pruning in health and disease Because CD11b/CR3 is the receptor that recognizes complement-tagged synapses, it sits at the center of a growing research effort to understand whether blocking this pathway could slow synapse loss in neurodegeneration. The research is still largely preclinical, but it represents one of the more surprising expansions of CD11b biology beyond its traditional immunological territory.